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ABSTRACT
Objective: To assess the association between male
circumcision and Neisseria gonorrhoeae, Chlamydia
trachomatis and Trichomonas vaginalis using data from a
male circumcision randomised controlled trial.
Methods: We used data collected during the male
circumcision trial conducted in Orange Farm (South
Africa) among men aged 18–24 years. Altogether, 1767
urine samples collected during the final follow-up visit
were analysed using PCR. Prevalence of N gonorrhoeae,
C trachomatis and T vaginalis was assessed as a function
of male circumcision using odds ratios (OR) given by
univariate and multivariate logistic regression.
Results: In an intention-to-treat analysis, prevalence of
N gonorrhoeae, C trachomatis and T vaginalis among
intervention and control groups were 10.0% versus 10.3%
(OR 0.97; p=0.84), 2.1% versus 3.6% (OR 0.58;
p=0.065) and 1.7% versus 3.1% (OR 0.54; p=0.062),
respectively. The association between T vaginalis and
male circumcision remained borderline when controlling
for age, ethnic group, number of lifetime partners, marital
status, condom use and HIV status (AOR 0.48;
p=0.069). In the as-treated analysis, this association
became significant (OR 0.49, p=0.030; AOR 0.41,
p=0.030).
Conclusions: This study demonstrates for the first time
that male circumcision reduces T vaginalis infection
among men. This finding explains why women with
circumcised partners are less at risk for T vaginalis
infection than other women. The protective effect on
T vaginalis is an additional argument to recommend male
circumcision in Africa where it is acceptable.
Trial registration number: NCT00122525.
Recent evidence has shown that male circumcision
is a promising prevention approach for sexually
transmitted infections (STIs): three randomised
controlled trials (RCTs)
1–3 have shown that male
circumcision reduces HIV infection among young
men in Africa. According to a meta-analysis
published in 2006, circumcised men may be at
lower risk of herpes simplex virus 2 (HSV-2)
infection, chancroid and syphilis.
4 However, there
are conflicting results about the association of male
circumcision and non-ulcerative STIs such as
Neisseria gonorrhoeae, Chlamydia trachomatis
5–11 and
Trichomonas vaginalis infections among men.
12–14
Infection with non-ulcerative STIs is major
public health issue. There are about 62 million
new cases of N gonorrhoeae annually worldwide,
with an estimated incidence of 17 million in sub-
Saharan Africa.
15 N gonorrhoeae is asymptomatic in
only 10% of men but primarily asymptomatic in
women and its complications can be lethal.
15
C trachomatis worldwide incidence has been esti-
mated at 92 million annually, with about 16
million occurring in sub-Saharan Africa.
15 It is a
significant public health concern because C tracho-
matis infection is asymptomatic in over 50% of
cases among men and women
15 and it can lead to
serious health complications if untreated.
16 Finally,
T vaginalis is the most common non-viral STI in
the world, with 174 million new cases estimated in
1999.
15 In sub-Saharan Africa, the incidence is
estimated at 32 million.
15 The infection is asymp-
tomatic in about 50% of infected women and in
over 90% of men;
15 thus, re-infection and re-
exposure is problematic.
17 Furthermore, co-infec-
tions among these three STIs are common.
18 19
The objective of this study was to analyse the
effect of male circumcision on N gonorrhoeae,
C trachomatis and T vaginalis prevalence using data
collected during a male circumcision RCT con-
ducted in Orange Farm, South Africa.
1
METHODS
Collection of data
The technical details of the trial (ANRS-1265 study),
including the description of the population, has been
published elsewhere.
1 Between February 2002 and
July 2004, 3274 uncircumcised male volunteers, aged
18 to 24 years, signed a consent form and were
recruited,randomisedintotwogroupsandfollowed-
up. Malecircumcision was offered immediately after
randomisation to the intervention group and after
the end of the follow-up period to control group
participants. Duringeach follow-up visit at 3,12 and
21 months, circumcision status was assessed by a
nurse through genital examination, a blood sample
was taken and information about sexual behaviour
was collected.
For 318 consecutive days, between 10 January
2005 and 24 November 2005, a 10 ml sample of first-
voided urine was collected from all participants
coming for the 21-month visit during this period.
These samples were analysed to assess the associa-
tion between male circumcision and N gonorrhoeae,
C trachomatis and Tv a g i n a l i sprevalence.
Laboratory methods
Urine samples were frozen at 220uC immediately
after collection and kept frozen until processing.
N gonorrhoeae and C trachomatis testing was
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Molecular Diagnostics, Pleasanton, California, USA). For the
detection of T vaginalis, a qualitative FRET-based real-time PCR
diagnostic test (Roche Molecular Diagnostics) was used based
on previous published literature and validated using charac-
terised specimens.
20 21 PCR has been shown to identify
significantly more trichomoniasis cases than culture.
22
Data analysis
Categorical data of the control and intervention groups were
compared using x
2 or Fisher exact test when appropriate and
numerical data were compared using the Kruskal-Wallis test.
N gonorrhoeae, C trachomatis and T vaginalis positive samples
were analysed using intention-to-treat and as-treated analyses
with univariate logistic regression. These analyses were repeated
multivariately to control for ethnic group, education, age,
number of lifetime partners, marital status, condom use and
HIV status. To assess whether the effect of male circumcision
on T vaginalis was independent of HIV infection, which is
reduced by male circumcision
1–3 and associated with T vaginalis
infection,
23 the analysis of the association between T vaginalis
and male circumcision was repeated a) among those who
remained HIV negative during follow-up and b) excluding those
who were HIV positive at recruitment. To evaluate the effect of
an imbalance between the groups, analyses of significant results
were repeated when controlling for the propensity score coded
in quintiles.
24
RESULTS
The baseline characteristics of the participants who were tested
for C trachomatis, N gonorrhoeae and T vaginalis by randomisa-
tion group are reported in table 1. The characteristics of those
who did not attend follow-up visits during which biological
samples were collected but who came for the last follow-up visit
are also reported in table 1. Randomisation groups differed
according to their ethnic distribution, the number of sex acts
and HIV status. When compared with study participants, those
not tested for C trachomatis, N gonorrhoeae and T vaginalis had a
higher number of lifetime partners and a higher HIV prevalence.
Tables 2–4 present the univariate and multivariate association
between male circumcision and N gonorrhoeae, C trachomatis and
T vaginalis, respectively. It was found that there was no effect of
male circumcision on N gonorrhoeae, as demonstrated by the
odds ratio (OR) values close to 1 in table 2. The borderline
association between male circumcision and C trachomatis in the
intention-to-treat analysis disappeared in the as-treated analy-
sis. The borderline association between male circumcision and
T vaginalis in the intention-to-treat analysis became significant
in the univariate and multivariate as-treated analysis. The
adjusted ORs were slightly lower than the corresponding
univariate ORs with values close to 0.5.
When excluding those who HIV seroconverted during follow-
up, the OR values reported in table 4 remained almost
unchanged with relative variation between 27.3% and +3.7%
(results not shown). This indicates that the effect of male
circumcision on T vaginalis is independent of the effect of male
circumcision on HIV.
When excluding those who were HIV positive at recruitment,
the OR values and p values reported in table 4 became slightly
lower. The OR and adjusted OR (AOR) associated with
randomisation groups were 0.45 (95% CI 0.22 to 0.89;
p=0.023) and 0.39 (95% CI 0.19 to 0.80; p=0.0098),
respectively. The OR and AOR associated with circumcision
status were 0.34 (95% CI 0.14 to 0.82; p=0.016) and 0.39 (95%
CI 0.18 to 0.76; p=0.065), respectively. The AORs of table 4
were almost identical when the analyses were adjusted for the
propensity score in addition to the other covariates.
DISCUSSION
This study demonstrates that male circumcision does not have a
protective effect on C trachomatis acquisition in men, which
concurs with the findings from most studies exploring this
association whether assessed in cross-sectional studies
582 52 6
or in cohort studies.
8–11 27 Only one multi-site study pooling
Table 1 Background characteristics, reported sexual behaviour and HIV prevalence at the 21-month visit
Control Intervention*
All participants
tested (control +
intervention)
Participants not
tested for CT, NG and
TV{
n=881 n=886 (p value) n=1767* n=1188 (p value)
Background characteristics
Ethnic group
Sotho 53.0% 54.0% (0.012) 53.5% 40.6% (,0.001)
Zulu 33.52% 28.3% 30.9% 42.3%
Other 13.5% 17.7% 15.6% 17.1%
,21 years old 33.3% 29.1% (0.065) 31.2% 32.9% (0.33)
Primary level of education completed 98.9% 98.0% (0.18) 98.4% 98.1% (0.48)
Married or living as married1 4.7% 5.7% (0.45) 5.2% 7.1% (0.061)
Reported sexual behaviour
Mean (median) number of lifetime sex
partners
4.2 (4.0) 4.4 (4.0) (0.55) 4.3 (4.0) 4.8 (4.0) (,0.001)
Mean (median) number of non-spousal sex
partners{
0.88 (1.0) 0.94 (1.0) (0.48) 0.91 (1.0) 0.87 (1.0) (0.73)
Mean (median) number of sex acts{ 7.4 (2.0) 9.0 (3.0) (0.045) 8.2 (3.0) 7.0 (3.0) (0.65)
Consistent condom use with non-spousal
sex partners{"
23.4% 24.6% (0.70) 24.1% 5.2% (,0.001)
HIV prevalence
HIV positive 7.1% 4.5% (0.025) 5.8% 8.0% (0.02)
*The p value corresponds to the comparison of the control and intervention group; {the p value corresponds to the comparison of
those tested for Neisseria gonorrhoeae (NG), Chlamydia trachomatis (CT) and Trichomonas vaginalis (TV) with those not tested;
{during the past 12 months; 1at some time during the past 12 months; "among those having had sexual intercourse during the
past 12 months.
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Philippines, Brazil, Colombia and Spain found that when
controlling for the number of sexual partners of the couple,
male circumcision was associated with an 82% reduction in the
risk of C trachomatis infection in female partners (OR 0.18, 95%
CI 0.05 to 0.58). However, C trachomatis infection was not
ascertained in the men themselves in that study and the authors
admit that it is possible that male circumcision reduces the risk
of transmission of the infection to the partner without reducing
the risk of C trachomatis acquisition in the men themselves.
16 In
fact, two studies seem to suggest that C trachomatis prevalence
is higher among circumcised men and their partners.
92 7
This study has some limitations. Biological samples were not
collected throughout the follow-up period, so the C trachomatis,
N gonorrhoeae and T vaginalis statuses at inclusion are unknown.
As a result, some T vaginalis infections may have predated the
intervention. Thus, we report the effect of male circumcision on
T vaginalis prevalence and not T vaginalis incidence. Only
participants coming for the last follow-up visit and during a
specified time period were tested for C trachomatis, N gonorrhoeae
and T vaginalis. This may have introduced some bias. Indeed, we
found that those having undergone STIs testing were slightly
different from those who had not. However, this difference was
not expected to change the association between male circumci-
sion and the C trachomatis, N gonorrhoeae and T vaginalis
statuses. Lastly, the slight difference between circumcised and
uncircumcised participants, which may be partly explained by a
differential follow-up, may also have interfered with the result
of this study. Hence, the fact that the results were not changed
when adjusting on the propensity score is reassuring.
Nevertheless, the results of this study have to be confirmed
using the data of the two other male circumcision trials
conducted in Kenya and Uganda.
23
No evidence of a protective effect of male circumcision on
N gonorrhoeae infection was found. Previous studies have
suggested that results will vary according to the population
assessed: four studies among male attendees of STI clinics in
developed countries found that uncircumcised men were up to
twice as likely to develop N gonorrhoeae infection than
circumcised men (OR of 1.6 to 2.0).
782 62 8However, none of
the studies conducted in developing countries found evidence of
such an effect.
692 72 9
The study demonstrated a borderline protection effect of
male circumcision on T vaginalis infection by young men in the
intention-to-treat analysis and a significant effect in the as-
treated analysis. The difference between the two analyses may
have been caused by the high proportion of cross-over in this
RCT,
1 which diluted the effect observed in the intention-to-
treat analysis. The fact that the protective effect became slightly
stronger in the multivariate analysis, which includes HIV
status, also suggests a protective independent effect of male
circumcision on T vaginalis acquisition.
Table 2 Association between Neisseria gonorrhoeae (NG) prevalence and male circumcision
NG prevalence %
(positive/total) OR (95% CI; p value) AOR* (95% CI; p value)
Randomisation group
Control 10.3% (91/881) 1 1
Intervention 10.0% (89/886) 0.97 (0.71 to 1.32; p=0.84) 0.94 (0.69 to 1.29; p=0.72)
Circumcision status
Uncircumcised 10.0% (88/878) 1 1
Circumcised 10.4% (92/887) 1.04 (0.76 to 1.41; p=0.81) 1.02 (0.74 to 1.40; p=0.91)
*Adjusted odds ratio on ethnic group, age, education, number of lifetime partners, marital status, condom use and HIV status.
Table 3 Association between Chlamydia trachomatis (CT) prevalence and male circumcision
CT prevalence %
(positive/total) OR (95% CI; p value) AOR* (95% CI; p value)
Randomisation group
Control 3.6% (32/881) 1 1
Intervention 2.1% (19/886) 0.58 (0.33 to 1.03; p=0.065) 0.56 (0.32 to 1.00; p=0.052)
Circumcision status
Uncircumcised 3.3% (29/878) 1 1
Circumcised 2.5% (22/887) 0.74 (0.42 to 1.31; p=0.30) 0.75 (0.42 to 1.32; p=0.31)
*Adjusted odds ratio on ethnic group, age, education, number of lifetime partners, marital status, condom use and HIV status.
Table 4 Association between Trichomonas vaginalis (TV) prevalence and male circumcision
TV prevalence %
(positive/total) OR (95% CI; p value) AOR* (95% CI; p value)
Randomisation group
Control 3.1% (27/881) 1 1
Intervention 1.7% (15/886) 0.54 (0.29 to 1.03; p=0.062) 0.53 (0.28 to 1.02; p=0.056)
Circumcision status
Uncircumcised 3.2% (28/878) 1 1
Circumcised 1.6% (14/887) 0.49 (0.25 to 0.93; p=0.030) 0.47 (0.25 to 0.92; p=0.027)
*Adjusted odds ratio on ethnic group, age, number of lifetime partners, marital status, condom use and HIV status, excluding
education because of the limited number of cases.
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investigated this association in men—probably due to diagnos-
tic limitations.
14 17–19 Nevertheless, the size of the protective
effect obtained in this study is consistent with what has been
estimated by observational studies. A cross-sectional investiga-
tion conducted among men from the general population of
Mwanza, Tanzania, found that male circumcision status was
significantly associated with T vaginalis infection (OR 0.37, 95%
CI 0.19 to 0.72) when adjusting for age.
12 In their prospective
study among US male partners of women infected with
T vaginalis, Sen ˜a and colleagues found that uncircumcised
men were almost twice as likely to be infected with T vaginalis
(unadjusted OR 1.8, 95% CI 1.10 to 3.20).
14
The fact that N gonorrhoeae and C trachomatis are almost
exclusively urethral pathogens may explain why male circumci-
sion has no protective effect against them. In contrast, the
protective effect against T vaginalis may indicate that T vaginalis
is both a sub-preputial and a urethral pathogen.
There is also evidence that male circumcision reduces
T vaginalis acquisition by female partners. A recent randomised
study conducted in Rakai, Uganda, among HIV discordant
heterosexual couples indicated that the rate of T vaginalis
infection among partners of participants from the intervention
arms was reduced by almost half (adjusted risk ratio 0.52, 95%
CI 0.05 to 0.98).
13 Hence, our study illustrates why male
circumcision is protective against T vaginalis infection among
women having circumcised partners. Indeed, as shown in our
study, male circumcision reduces the risk of T vaginalis infection
among men and consequently reduces the exposure of women
to T vaginalis. Thus, the risk of T vaginalis infection is lowered
among women.
Some studies have suggested that T vaginalis facilitates the
spread of HIV by up to twofold.
15 23 30 31 Thus, the effect of male
circumcision on HIV acquisition in young men may partly be
due to its effect on T vaginalis. If the results of this study are
confirmed by those of the male circumcision trials conducted in
Uganda and Kenya, the findings of this study will reinforce the
WHO-UNAIDS statement recommending the implementation
of male circumcision programmes in African countries with low
male circumcision prevalence and a high male circumcision
acceptability.
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